⚠️ Important Notice

This page is produced by Ocxly Neuro Labs strictly for educational and informational purposes only. It must not be construed as professional medical advice, diagnosis, or treatment of any kind.

🚫 Not written by medical professionals. The authors and editors at Ocxly Neuro Labs are not licensed medical, psychiatric, or healthcare professionals. This content is an educational synthesis of publicly available, peer-reviewed literature — not clinical guidance.

🤖 AI-assisted research. This article was researched and structured with the assistance of Artificial Intelligence (AI) under human editorial oversight. All clinical claims are attributed to peer-reviewed sources, but AI-generated content may contain errors. Always verify medical information with a qualified clinician.

Always consult a qualified, licensed healthcare provider for any medical concerns. Ocxly Neuro Labs assumes no liability for use of this content in clinical or personal health decisions.

NEUROSCIENCE SERIES

Understanding Fibromyalgia

A definitive, evidence‑based resource on fibromyalgia — a chronic disorder of central nervous system pain processing — for clinicians, researchers, and people living with it.

Last updated: 20 September 2026

Conceptual illustration of a human figure with a luminous glow tracing the brain and spinal cord, symbolising that fibromyalgia pain is generated within the central nervous system.
central sensitization · widespread pain · nociplastic
⚠️ CRITICAL MEDICAL DISCLAIMER
This article is for educational purposes only and does not constitute medical advice. Diagnosis and treatment of fibromyalgia must be conducted by a licensed healthcare professional. Medication information is for reference only. In an emergency, call emergency services.
🚫 Not written by medical professionals. Ocxly Neuro Labs authors are not licensed clinicians. This is a lay educational synthesis of published research — not clinical guidance. Always consult a qualified healthcare provider.
🤖 AI-assisted content. This article was researched and structured with the assistance of AI under human editorial oversight. All clinical claims are attributed to peer-reviewed sources, but AI-generated content may contain errors.
01 — DEFINITION & EPIDEMIOLOGY

What is Fibromyalgia?

A figure with a glowing brain and spinal cord surrounded by normal-looking X-ray panels of the skull, chest, spine, shoulder and knee.
The “invisible illness”: standard X-rays and blood tests are typically normal, yet the pain is neurologically real. (Conceptual illustration.)

Fibromyalgia is best defined not as a disease of the muscles or joints but as a chronic disorder of central nervous system pain processing — a condition in which the brain and spinal cord amplify and misinterpret ordinary sensory signals, producing widespread pain, fatigue, unrefreshing sleep, and cognitive difficulty in the absence of tissue damage or inflammation.[1][2] The historical name fibrositis implied inflammation of fibrous tissue that was never actually found.[9]

~2–8%
Estimated prevalence range (criteria-dependent)[1]
~2%
US adults (~4 million), 2012 NHIS[14]
~3:1
Female : male ratio with modern criteria (men underdiagnosed)[15]
~3×
Elevated CSF substance P vs controls[6]

Fibromyalgia can begin at any age but is most often recognised in middle adulthood.[2] It is diagnosed far more often in women than men — historically at ratios above 9:1 in clinic populations — but this gap narrows dramatically (to roughly 2–3:1) when researchers apply modern symptom-based criteria to the general population rather than relying on specialist referrals, strongly suggesting that men with fibromyalgia are substantially underdiagnosed.[15][1] Because standard blood tests, X-rays, and inflammatory markers are typically normal, patients have long faced skepticism — yet functional brain imaging shows the pain is neurologically real rather than imaginary.[1][7]

Fibromyalgia is not "pain without a cause." It is the prototype of nociplastic pain — pain arising from altered nociceptive processing in the central nervous system, in the absence of clear tissue damage or nerve injury.
— Editorial summary, based on Clauw DJ, JAMA (2014).[1]
02 — CORE MECHANISM

Central Sensitization: The Amplified Pain System

Signals from the body travelling to the brain and spinal cord and being amplified, with a turned-up volume dial and an EEG-style waveform.
Central sensitization: ordinary signals from the body are amplified as they pass through the spinal cord and brain — the pain system’s “volume” is turned up. (Conceptual illustration.)

The central concept is central sensitization: neurons in the spinal cord and brain become hyper-responsive, so the pain system's "volume knob" is turned up. Two hallmarks appear on testing — hyperalgesia (an exaggerated response to genuinely painful stimuli) and allodynia (pain from stimuli that should not hurt, such as light touch or mild pressure).[1][2]

🧪 Neurotransmitter imbalance

The neurochemistry tips toward facilitating pain and away from inhibiting it. Cerebrospinal-fluid studies found substance P about three times higher in fibromyalgia patients than in controls,[6] and brain spectroscopy shows elevated glutamate (the main excitatory neurotransmitter) in the insula, correlating with experimental pain.[8] Meanwhile the descending pathways that dampen pain — driven by serotonin and norepinephrine — appear underactive, which is part of why drugs that raise those transmitters help.[1]

🧲 Brain-imaging evidence

Functional MRI made the case visible. In a landmark 2002 study, the same mild pressure produced far greater activation in pain-processing regions in fibromyalgia patients than in controls — objective evidence that identical input is amplified centrally.[7] Later imaging extended this to altered connectivity within the brain's pain networks.[1][8]

😴 Non-restorative sleep

As far back as 1975, researchers documented an alpha-EEG (alpha–delta) intrusion — fast "waking" brain-wave activity breaking into deep non-REM sleep — and showed that depriving healthy volunteers of deep sleep could reproduce fibromyalgia-like aches, implicating non-restorative sleep in the disorder itself.[9]

⚡ Autonomic dysregulation

Research also points to imbalance in the autonomic nervous system, with relative sympathetic ("fight or flight") overactivity and reduced heart-rate variability — thought to contribute to unrefreshing sleep, fatigue, and other symptoms as a contributing feature rather than the sole cause.[2]

ℹ️ Why it affects the whole body. Because this is a systemic nervous-system phenomenon rather than a local joint problem, fibromyalgia can affect nearly every body region and system at once, rather than being confined to specific joints.[1][2]
03 — CLINICAL PRESENTATION

The Symptom Profile

A seated figure surrounded by overlapping translucent circles representing pain, fatigue, cognitive fog and sensory overload.
Fibromyalgia is more than pain — widespread pain, profound fatigue, “fibro fog,” and sensory overload overlap and fluctuate together. (Conceptual illustration.)
🔥

Widespread, migratory pain

The defining symptom is pain that is widespread — above and below the waist and on both sides of the body — often aching, burning, throbbing, or electrical, and characteristically moving and fluctuating across regions from day to day.[1][3]

🔋

Profound fatigue & poor sleep

Fatigue is disproportionate and not relieved by rest. Sleep is non-restorative, tied to the alpha-EEG intrusion into deep sleep first described in 1975.[9][2]

🌫️

Cognitive dysfunction ("fibro fog")

Patients report trouble with short-term memory, word-finding, concentration, mental multitasking, and filtering out background noise — a recognised core feature captured in modern diagnostic criteria.[2][5]

🔆

Sensory amplification beyond pain

Central sensitization is not limited to pain. Many patients experience heightened sensitivity to bright light, loud sound, strong odors, and temperature extremes — a general "turning up" of sensory processing.[1][2]

Symptom domainTypical presentationEveryday impact
PainWidespread, migratory, aching/burning; hyperalgesia & allodyniaReduced activity, disrupted work, guarding of touch
FatiguePersistent, disproportionate, unrelieved by restLimited stamina, reduced participation
SleepUnrefreshing sleep; frequent awakenings; alpha-intrusionAmplified pain and fatigue the next day
Cognition"Fibro fog": memory, word-finding, concentrationWork errors, lost items, mental exhaustion
SensorySensitivity to light, sound, odor, temperatureOverwhelm in busy environments
04 — TRIGGERS & RISK FACTORS

What Sets Fibromyalgia in Motion

A balance beam with stones labelled genes, injury, infection and stress tipping the scale toward 'symptoms begin'.
A tipping-point model: genetic predisposition plus a trigger — injury, infection, or severe stress — can set central sensitization in motion. (Conceptual illustration.)

🧬 Genetic predisposition

Fibromyalgia clusters in families. A formal family study found first-degree relatives of a person with fibromyalgia had roughly 8.5 times the odds of having it themselves versus relatives of controls, and it co-aggregated with mood disorders — pointing to partly inherited biology in pain- and mood-relevant systems.[12]

💥 Physical or psychological trauma

Onset is frequently triggered by a physical stressor — a motor-vehicle accident, spinal injury, or surgery — or by severe psychological stress, which appear to precipitate central sensitization in predisposed individuals.[1][2]

🦠 Post-infectious onset

Certain infections have been linked to triggering the syndrome. This gained fresh attention with COVID-19: a survey study found a meaningful proportion of people meeting fibromyalgia criteria did so after SARS-CoV-2 infection, positioning fibromyalgia within the post-COVID / "long COVID" spectrum.[13] Epstein–Barr virus and Lyme disease are also commonly cited, though causality is harder to prove.[2]

🩺 Rheumatic comorbidity

People already living with autoimmune or inflammatory rheumatic diseases — rheumatoid arthritis, lupus, ankylosing spondylitis — have markedly higher rates of concurrent fibromyalgia, which can complicate diagnosis because the extra pain is easy to blame on the primary disease.[1][2]

05 — DIAGNOSTIC EVOLUTION

From Tender Points to Symptom Scales

Split panel contrasting the 1990 map of 18 tender points with the modern Widespread Pain Index and Symptom Severity scale on a tablet.
From tender points to symptom scales: the shift from the 1990 tender-point exam to the 2010/2016 Widespread Pain Index and Symptom Severity scale. (Conceptual illustration; the regions and items shown are indicative.)

📍 The 1990 ACR criteria

The original 1990 ACR classification criteria required widespread pain plus tenderness at at least 11 of 18 specific "tender points" pressed by the examiner.[3] Useful for research, this proved awkward in clinic — tender-point exams were inconsistently performed and ignored the non-pain symptoms patients found most disabling.

📊 The 2010 / 2016 criteria

The 2010 preliminary criteria replaced the tender-point exam with two patient-reported scales: the Widespread Pain Index (WPI), a 0–19 count of painful regions, and the Symptom Severity (SS) scale (0–12) grading fatigue, unrefreshing sleep, cognitive symptoms, and somatic complaints.[4] The 2016 revision refined the thresholds and added a generalized-pain requirement to reduce misclassification.[5]

✅ Positive diagnosis, not just exclusion

The field has shifted toward diagnosing fibromyalgia positively, on the strength of its characteristic clinical picture, rather than treating it only as a diagnosis of exclusion — while still ruling out mimics such as hypothyroidism, inflammatory arthritis, and multiple sclerosis where the history warrants it.[1][5] In the broader pain taxonomy, fibromyalgia is now the prototype of nociplastic pain — a third mechanistic category alongside nociceptive and neuropathic pain.[1]

06 — CO-OCCURRING CONDITIONS

Fibromyalgia Rarely Travels Alone

A constellation diagram linking fibromyalgia to IBS, migraine, interstitial cystitis, TMJ disorders, restless legs and anxiety/depression.
Fibromyalgia overlaps with other central-sensitivity conditions — IBS, migraine, interstitial cystitis, TMJ disorders, restless legs, and anxiety/depression. (Conceptual illustration.)

It overlaps heavily with other "central sensitivity" conditions, and recognising the overlaps matters clinically — treating one (for example, a drug that helps both pain and mood) can help several at once.[1][2]

🌀

Gastrointestinal

Irritable bowel syndrome (IBS) and gastro-oesophageal reflux (GERD).[1]

🤕

Neurological

Chronic migraine, tension-type headache, and restless legs syndrome.[2]

💧

Urologic / pelvic

Interstitial cystitis (painful bladder syndrome) and chronic pelvic pain.[1]

😬

Orofacial

Temporomandibular joint (TMJ) disorders.[1]

🧠 Depression & anxiety

Clinical depression and anxiety disorders occur at high rates — driven both by shared neurobiology (serotonin/norepinephrine systems) and by the genuine burden of living with unremitting pain and fatigue.[2][12] If low mood becomes overwhelming, please reach out — see Crisis Support below.

07 — EVIDENCE-BASED TREATMENT

A Multimodal Approach

A four-part wheel showing movement, mind-based therapy, medication and sleep as the pillars of fibromyalgia management.
A multimodal plan: movement, mind-based therapies, sleep, and medication work together — no single lever does it alone. (Conceptual illustration.)
⚕️ PHARMACOTHERAPY DISCLAIMER: All medication information is educational. Prescribing must be individualised by a clinician. Guidelines emphasise a stepped, multimodal plan built on non-drug foundations, with medication as an adjunct.[10]
MedicationClass / mechanismStatus & notes
Pregabalin (Lyrica)α2δ calcium-channel ligand (calms neuronal excitability)FDA-approved for fibromyalgia (2007) — the first approved[16][1]
Duloxetine (Cymbalta)SNRI (boosts descending pain inhibition)FDA-approved (2008)[16]
Milnacipran (Savella)SNRIFDA-approved (2009)[16]
Cyclobenzaprine, sublingual (TNX-102 SL)Muscle relaxant / centrally acting (bedtime)Reported as a more recent FDA-approved agent[16]
Amitriptyline; cyclobenzaprine (oral)Tricyclic / muscle relaxant (low dose, for sleep & pain)Commonly used off-label[10][1]
Low-dose naltrexone (LDN)Opioid antagonist (low dose; investigational)Small trial: ~29% vs ~18% pain reduction vs placebo — promising, low certainty[11]
NSAIDs (ibuprofen) & opioidsPeripheral anti-inflammatory / opioid analgesicsGenerally ineffective for centrally generated pain; opioids may worsen it and carry harms[1]

🏃 Movement as medicine

Counterintuitively for a pain condition, graded low-impact aerobic exercise is the single best-supported intervention — the EULAR guideline rates exercise as its only "strong for" recommendation.[10] Warm-water (aquatic) therapy, tai chi, and gentle walking, started low and increased slowly, help retrain the nervous system while avoiding the flare a sudden hard workout can provoke.

🧩 Psychological therapies

Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) are recommended — not because the illness is "in the mind," but because they teach pacing, sleep skills, and ways to reduce the distress and catastrophizing that amplify pain signals.[10][1]

08 — DAILY MANAGEMENT & LIFESTYLE

Living Well Day to Day

A weekly pacing planner on a desk with balanced activity and rest blocks, a sleep mask, a mug, and spoons representing Spoon Theory.
Pacing and the “energy envelope”: planning activity around rest to avoid the push–crash cycle, echoing the Spoon Theory. (Conceptual illustration.)
🥄

Pacing & the "energy envelope"

A cornerstone of self-management is avoiding the push–crash cycle: overdoing activity on a good day, then paying with days of flare. The widely shared "Spoon Theory" (coined by patient-advocate Christine Miserandino) is a practical metaphor for a finite daily energy budget, helping patients plan and prioritise rather than boom-and-bust.

🌙

Sleep optimisation

Because unrefreshing sleep is central to the biology,[9] consistent sleep–wake timing, a cool dark quiet bedroom, limiting caffeine/alcohol and evening screens, and treating co-existing sleep disorders (restless legs, apnoea) are foundational rather than optional.[1]

🤝

Build the right team

Fibromyalgia is best handled by a multidisciplinary team — often a primary-care physician or rheumatologist to coordinate, plus physical therapy and psychological support — with the patient as an informed, active partner.[10][1]

09 — RESEARCH FRONTIERS

Future Directions

A research montage showing a blood biomarker tube, a non-invasive brain-stimulation coil over the head, and before/after neural connectivity.
Research frontiers: candidate blood biomarkers, non-invasive neuromodulation such as TMS, and harnessing neuroplasticity. These remain investigational. (Conceptual illustration.)

🔬 Objective biomarkers

A major goal is a definitive, objective test. Researchers are exploring blood-based signatures — inflammatory cytokine patterns, RNA/gene-expression profiles, and metabolomic/spectroscopic fingerprints — but as of now no blood test is validated for clinical diagnosis, which remains clinical.[1][2]

🧲 Neuromodulation

Techniques that aim to "re-tune" the sensitized nervous system are under study, including transcranial magnetic stimulation (TMS) and vagus-nerve stimulation; guideline bodies currently regard these as investigational with limited or mixed evidence.[10]

🌿 Cannabinoids

Medicinal cannabis and the role of the endocannabinoid system are of intense patient interest, but the evidence base is still weak and guidelines stop short of endorsing them.[10]

🔁 The throughline: neuroplasticity. If the nervous system can learn to amplify pain, it may — with the right combination of movement, therapy, sleep, and targeted drugs — be helped to unlearn it. Fibromyalgia is typically managed rather than cured, but many people achieve meaningful, lasting improvement.[1][10]

🆘 Crisis Support — You Are Not Alone

Living with chronic pain can take a heavy toll on mood. If you or someone you love is in immediate danger or having thoughts of suicide, please reach out now. The crisis lines below are free, confidential, and most operate 24/7.

988
🇺🇸 USA — 988 Suicide & Crisis Lifeline[17]
9-8-8
🇨🇦 Canada — Suicide Crisis Helpline[18]
116 123
🇬🇧 UK & ROI — Samaritans[19]
13 11 14
🇦🇺 Australia — Lifeline[20]
1737
🇳🇿 New Zealand — Need to Talk?[21]
14416
🇮🇳 India — Tele-MANAS (Govt. of India)[22]
also 1-800-891-4416
1860-266-2345
🇮🇳 India — Vandrevala Foundation (24×7)[23]

Outside these regions, or for a worldwide directory of crisis centres, visit the IASP global directory[24]. In any life-threatening emergency, call your local emergency number (e.g., 911 in US/Canada, 999 in UK, 000 in Australia, 111 in NZ, 112 in EU/India).

10 — REFERENCES & SOURCES

Cited Sources

All sources below link to peer-reviewed publications, government health agencies, or authoritative clinical guidelines. Open-access PubMed Central (PMC), PubMed, or DOI links are provided wherever available. Bibliographic details were verified against primary sources.

  1. Clauw, D. J. (2014). Fibromyalgia: A Clinical Review. JAMA, 311(15), 1547–1555. DOI: 10.1001/jama.2014.3266. Publisher: JAMA Network. PubMed: PMID 24737367
  2. Häuser, W., Ablin, J., Fitzcharles, M.-A., et al. (2015). Fibromyalgia. Nature Reviews Disease Primers, 1, 15022. DOI: 10.1038/nrdp.2015.22. Publisher: nature.com/articles/nrdp201522
  3. Wolfe, F., Smythe, H. A., Yunus, M. B., et al. (1990). The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Arthritis & Rheumatism, 33(2), 160–172. DOI: 10.1002/art.1780330203
  4. Wolfe, F., Clauw, D. J., Fitzcharles, M.-A., et al. (2010). The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. Arthritis Care & Research, 62(5), 600–610. DOI: 10.1002/acr.20140. PubMed: PMID 20461783
  5. Wolfe, F., Clauw, D. J., Fitzcharles, M.-A., et al. (2016). 2016 Revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria. Seminars in Arthritis and Rheumatism, 46(3), 319–329. DOI: 10.1016/j.semarthrit.2016.08.012. PubMed: PMID 27916278
  6. Russell, I. J., Orr, M. D., Littman, B., et al. (1994). Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis & Rheumatism, 37(11), 1593–1601. DOI: 10.1002/art.1780371106. PubMed: PMID 7526868
  7. Gracely, R. H., Petzke, F., Wolf, J. M., & Clauw, D. J. (2002). Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis & Rheumatism, 46(5), 1333–1343. DOI: 10.1002/art.10225. PubMed: PMID 12115241
  8. Harris, R. E., Sundgren, P. C., Craig, A. D., et al. (2009). Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis & Rheumatism, 60(10), 3146–3152. DOI: 10.1002/art.24849. Free PMC: PMC2827610
  9. Moldofsky, H., Scarisbrick, P., England, R., & Smythe, H. (1975). Musculoskeletal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosomatic Medicine, 37(4), 341–351. PubMed: PMID 169541
  10. Macfarlane, G. J., Kronisch, C., Dean, L. E., et al. (2017). EULAR revised recommendations for the management of fibromyalgia. Annals of the Rheumatic Diseases, 76(2), 318–328. DOI: 10.1136/annrheumdis-2016-209724. PubMed: PMID 28476880
  11. Younger, J., Noor, N., McCue, R., & Mackey, S. (2013). Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis & Rheumatism, 65(2), 529–538. DOI: 10.1002/art.37734
  12. Arnold, L. M., Hudson, J. I., Hess, E. V., et al. (2004). Family study of fibromyalgia. Arthritis & Rheumatism, 50(3), 944–952. DOI: 10.1002/art.20042. PubMed: PMID 15022338
  13. Ursini, F., Ciaffi, J., Mancarella, L., et al. (2021). Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey. RMD Open, 7(3), e001735. DOI: 10.1136/rmdopen-2021-001735
  14. Walitt, B., Nahin, R. L., Katz, R. S., Bergman, M. J., & Wolfe, F. (2015). The prevalence and characteristics of fibromyalgia in the 2012 National Health Interview Survey. PLOS ONE, 10(9), e0138024. DOI: 10.1371/journal.pone.0138024. Free PMC: PMC4575027
  15. Wolfe, F., Walitt, B., Perrot, S., Rasker, J. J., & Häuser, W. (2018). Fibromyalgia diagnosis and biased assessment: sex, prevalence and bias. PLOS ONE, 13(9), e0203755. DOI: 10.1371/journal.pone.0203755. Publisher: journals.plos.org
  16. American Journal of Managed Care (AJMC). TNX-102 SL Now Fourth FDA-Approved Treatment for Fibromyalgia (reporting the FDA approvals of pregabalin, 2007; duloxetine, 2008; milnacipran, 2009; and a sublingual cyclobenzaprine formulation). Available: ajmc.com
  17. 988 Suicide & Crisis Lifeline (USA). SAMHSA / Vibrant Emotional Health. Available: 988lifeline.org; SAMHSA: samhsa.gov/mental-health/988
  18. 9-8-8: Suicide Crisis Helpline (Canada). Government of Canada / CAMH. Available: 988.ca
  19. Samaritans (UK & Republic of Ireland). 24-hour helpline: 116 123 (freephone). Available: samaritans.org
  20. Lifeline Australia. 24/7 crisis support: 13 11 14. Available: lifeline.org.au
  21. 1737 — Need to Talk? (New Zealand). National free 24/7 mental-health helpline (call or text 1737). Available: 1737.org.nz
  22. Tele-MANAS (India). Tele Mental Health Assistance and Networking Across States — a 24×7 free helpline by the Ministry of Health and Family Welfare, Government of India. Dial 14416 (or 1-800-891-4416). Official portal: telemanas.mohfw.gov.in
  23. Vandrevala Foundation Mental Health Helpline (India). 24×7 free crisis intervention helpline: 1860-266-2345. Available: vandrevalafoundation.com
  24. International Association for Suicide Prevention (IASP). Global Crisis Centres directory. Available: iasp.info/resources/Crisis_Centres
⚠️ Author & Educational-Purpose Disclaimer

The author of this article is not a medical, psychiatric, or healthcare professional. This page is offered strictly for educational and informational purposes only and is a synthesis of publicly available, peer-reviewed literature and official clinical guidelines. Nothing on this page constitutes — or should be construed as — medical advice, diagnosis, treatment, or a clinical recommendation, and it is not a substitute for consultation with a qualified, licensed healthcare provider. Diagnostic and treatment decisions for fibromyalgia (or any health condition) must always be made by a registered physician, rheumatologist, or other appropriately licensed clinician who has personally assessed the individual concerned. If you are unwell or in crisis, please contact your local healthcare provider, emergency services, or one of the crisis lines listed above.

🤖 AI Assistance Disclosure: This article was researched and structured with the assistance of Artificial Intelligence (AI) under human editorial oversight. All clinical claims are attributed to peer-reviewed sources. AI-generated content may contain errors or omissions — always verify medical information with a qualified clinician. Not a substitute for professional medical advice.

🚫 Non-Professional Authorship: The author(s) and editors at Ocxly Neuro Labs are not licensed medical, psychiatric, or healthcare professionals. This page is an educational synthesis of publicly available literature. Nothing here constitutes — or should be construed as — medical advice, clinical diagnosis, treatment, or a professional recommendation.

Privacy Policy | Terms & Conditions | Disclaimer | Help | Hyperlinking | Copyright | Trademark Disclosure